-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Anavex Life Sciences Analyst Ratings
Anavex Life Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/20/2023 | — | HC Wainwright & Co. | Reiterates | Buy → Buy | |
| 06/29/2023 | 548.26% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 05/02/2023 | 548.26% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/31/2023 | 548.26% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 02/09/2023 | 236.13% | BTIG | $35 → $28 | Maintains | Buy |
| 02/09/2023 | 500.24% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/06/2023 | 500.24% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/03/2023 | 500.24% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 12/06/2022 | 32.05% | Cantor Fitzgerald | $16 → $11 | Downgrades | Overweight → Neutral |
| 06/23/2022 | 380.19% | Berenberg | → $40 | Initiates Coverage On | → Buy |
| 02/02/2022 | 404.2% | HC Wainwright & Co. | $39 → $42 | Maintains | Buy |
| 09/23/2021 | 320.17% | BTIG | → $35 | Initiates Coverage On | → Buy |
| 06/28/2021 | 368.19% | HC Wainwright & Co. | $25 → $39 | Maintains | Buy |
| 06/15/2021 | 200.12% | HC Wainwright & Co. | $17 → $25 | Maintains | Buy |
| 02/23/2021 | 200.12% | Cantor Fitzgerald | $10 → $25 | Reiterates | → Overweight |
| 12/16/2020 | 104.08% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
| 10/21/2020 | 68.07% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
| 09/28/2020 | 44.06% | Ladenburg Thalmann | → $12 | Initiates Coverage On | → Buy |
| 03/16/2020 | 44.06% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/24/2019 | 92.08% | Dawson James | → $16 | Initiates Coverage On | → Buy |
| 06/18/2019 | 20.05% | Janney Montgomery Scott | → $10 | Initiates Coverage On | → Buy |
What is the target price for Anavex Life Sciences (AVXL)?
The latest price target for Anavex Life Sciences (NASDAQ: AVXL) was reported by HC Wainwright & Co. on July 20, 2023. The analyst firm set a price target for $0.00 expecting AVXL to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Anavex Life Sciences (AVXL)?
The latest analyst rating for Anavex Life Sciences (NASDAQ: AVXL) was provided by HC Wainwright & Co., and Anavex Life Sciences reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Anavex Life Sciences (AVXL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on July 20, 2023 so you should expect the next rating to be made available sometime around July 20, 2024.
Is the Analyst Rating Anavex Life Sciences (AVXL) correct?
While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a reiterated with a price target of $0.00 to $0.00. The current price Anavex Life Sciences (AVXL) is trading at is $8.33, which is out of the analyst's predicted range.
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/20/2023 | — | HC Wainwright & Co. | Reiterates | Buy → Buy | |
| 06/29/2023 | 548.26% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 05/02/2023 | 548.26% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/31/2023 | 548.26% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 02/09/2023 | 236.13% | BTIG | $35 → $28 | Maintains | Buy |
| 02/09/2023 | 500.24% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/06/2023 | 500.24% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/03/2023 | 500.24% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 12/06/2022 | 32.05% | Cantor Fitzgerald | $16 → $11 | Downgrades | Overweight → Neutral |
| 06/23/2022 | 380.19% | Berenberg | → $40 | Initiates Coverage On | → Buy |
| 02/02/2022 | 404.2% | HC Wainwright & Co. | $39 → $42 | Maintains | Buy |
| 09/23/2021 | 320.17% | BTIG | → $35 | Initiates Coverage On | → Buy |
| 06/28/2021 | 368.19% | HC Wainwright & Co. | $25 → $39 | Maintains | Buy |
| 06/15/2021 | 200.12% | HC Wainwright & Co. | $17 → $25 | Maintains | Buy |
| 02/23/2021 | 200.12% | Cantor Fitzgerald | $10 → $25 | Reiterates | → Overweight |
| 12/16/2020 | 104.08% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
| 10/21/2020 | 68.07% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
| 09/28/2020 | 44.06% | Ladenburg Thalmann | → $12 | Initiates Coverage On | → Buy |
| 03/16/2020 | 44.06% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/24/2019 | 92.08% | Dawson James | → $16 | Initiates Coverage On | → Buy |
| 06/18/2019 | 20.05% | Janney Montgomery Scott | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/20/2023 | — | HC Wainwright & Co. | 重申 | 购买 → 购买 | |
| 06/29/2023 | 548.26% | HC Wainwright & Co. | → 54 美元 | 重申 | 购买 → 购买 |
| 05/02/2023 | 548.26% | HC Wainwright & Co. | → 54 美元 | 重申 | → 购买 |
| 03/31/2023 | 548.26% | HC Wainwright & Co. | 50 美元 → 54 美元 | 维护 | 购买 |
| 02/09/2023 | 236.13% | BTIG | 35 美元 → 28 美元 | 维护 | 购买 |
| 02/09/2023 | 500.24% | HC Wainwright & Co. | → 50 美元 | 重申 | → 购买 |
| 02/06/2023 | 500.24% | HC Wainwright & Co. | → 50 美元 | 重申 | → 购买 |
| 01/03/2023 | 500.24% | HC Wainwright & Co. | 42 美元 → 50 美元 | 维护 | 购买 |
| 12/06/2022 | 32.05% | 坎托·菲茨杰拉德 | 16 美元 → 11 美元 | 降级 | 超重 → 中性 |
| 06/23/2022 | 380.19% | 贝伦贝格 | → 40 美元 | 启动覆盖开启 | → 购买 |
| 2022 年 2 月 2 日 | 404.2% | HC Wainwright & Co. | 39 美元 → 42 美元 | 维护 | 购买 |
| 2021 年 9 月 23 日 | 320.17% | BTIG | → 35 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 6 月 28 日 | 368.19% | HC Wainwright & Co. | 25 美元 → 39 美元 | 维护 | 购买 |
| 06/15/2021 | 200.12% | HC Wainwright & Co. | 17 美元 → 25 美元 | 维护 | 购买 |
| 2021 年 2 月 23 日 | 200.12% | 坎托·菲茨杰拉德 | 10 美元 → 25 美元 | 重申 | → 超重 |
| 2020 年 12 月 16 日 | 104.08% | HC Wainwright & Co. | 14 美元 → 17 美元 | 维护 | 购买 |
| 2020 年 10 月 21 日 | 68.07% | HC Wainwright & Co. | 12 美元 → 14 美元 | 维护 | 购买 |
| 09/28/2020 | 44.06% | 拉登堡塔尔曼 | → 12 美元 | 启动覆盖开启 | → 购买 |
| 03/16/2020 | 44.06% | HC Wainwright & Co. | → 12 美元 | 启动覆盖开启 | → 购买 |
| 07/24/2019 | 92.08% | 道森詹姆斯 | → 16 美元 | 启动覆盖开启 | → 购买 |
| 06/18/2019 | 20.05% | 詹尼蒙哥马利斯科特 | → 10 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Anavex Life Sciences (AVXL)?
Anavex Life Sciences (AVXL) 的目标价格是多少？
The latest price target for Anavex Life Sciences (NASDAQ: AVXL) was reported by HC Wainwright & Co. on July 20, 2023. The analyst firm set a price target for $0.00 expecting AVXL to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年7月20日公布了Anavex Life Sciences（纳斯达克股票代码：AVXL）的最新目标股价。这家分析公司将目标股价定为0.00美元，预计AVXL将在12个月内跌至-100.00％（可能下跌-100.00％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Anavex Life Sciences (AVXL)?
Anavex Life Sciences (AVXL) 的最新分析师评级是多少？
The latest analyst rating for Anavex Life Sciences (NASDAQ: AVXL) was provided by HC Wainwright & Co., and Anavex Life Sciences reiterated their buy rating.
Anavex Life Sciences（纳斯达克股票代码：AVXL）的最新分析师评级由HC Wainwright & Co. 提供，Anavex Life Sciences 重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Anavex Life Sciences (AVXL)?
Anavex Life Sciences（AVXL）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on July 20, 2023 so you should expect the next rating to be made available sometime around July 20, 2024.
分析师在进行了广泛的研究，包括浏览公开财务报表、与Anavex Life Sciences的高管和客户交谈以及听取财报电话会议后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Anavex Life Sciences的最后一次评级是在2023年7月20日提交的，因此你应该预计下一个评级将在2024年7月20日左右公布。
Is the Analyst Rating Anavex Life Sciences (AVXL) correct?
分析师对 Anavex Life Sciences (AVXL) 的评级是否正确？
While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a reiterated with a price target of $0.00 to $0.00. The current price Anavex Life Sciences (AVXL) is trading at is $8.33, which is out of the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的Anavex Life Sciences（AVXL）评级得到重申，目标股价为0.00美元至0.00美元。Anavex Life Sciences（AVXL）目前的交易价格为8.33美元，超出了分析师的预测区间。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧